DORADO

• Research type

  Research Study

• Full title

  early Detection Of neovascular age-Related mAcular Degeneration in the cOmmunity

• IRAS ID

  331617

• Contact name

  Richard Gale

• Contact email

  richard.gale@york.ac.uk

• Sponsor organisation

  University of York

• Duration of Study in the UK

  2 years, 5 months, 14 days

• Research summary

  Neovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the western world1 with an estimated 40,000 newly diagnosed cases in the UK every year2. The prevalence of AMD in the UK, including nAMD, is projected to double, affecting an average of 1.23 million individuals by 20503.
  Early detection and treatment4 is crucial in maintaining visual acuity and quality-of-life (QoL)5,6. Over the past 15 years, treatment for nAMD is available7 in the form of anti-VEGF intravitreal injections8. Early treatment of the second eye following detection by optical coherence tomography (OCT) is known to maintain better visual acuity and health related QoL and may reduce costs of health and social care over the lifetime of patients9. There is a paucity of information about the benefit and feasibility of monitoring people with dry degeneration, who are at risk of developing wet disease, for early detection of the disease in their first eye. OCT is now widely available in the community10 both in high street optometry practices and in diabetic screening programmes.

• REC name

  East of England - Cambridge Central Research Ethics Committee

• REC reference

  24/EE/0009

• Date of REC Opinion

  21 Feb 2024

• REC opinion

  Further Information Favourable Opinion